The Institute of Cancer Research (ICR) has published a new study stating that a genetic test has been found that predicts whether bone marrow cancer treatments, including thalidomide, are likely to cause peripheral neuropathy. All common treatment regimes for multiple myeloma, an aggressive cancer that affects a type of white blood cell in the bone marrow, contain at least one drug with the side-effect of neuropathy. The study raises the possibility that patients could have their blood screened for neuropathy risk genes. Â READ MORE
Source: Medical News Today